Test tube gut and liver alternative to animal testing
A group of Scottish scientists are developing a new way to test the toxicity of nanoparticles
The three-year, £2m, InLiveTox project brings together leaders in nanotoxicology from around the world, including Edinburgh Napier University, to develop a way of testing the toxicity of ingested nanoparticles that does not rely on animals. Instead, a test-tube gut and liver will emulate the response of cells and tissues to ingestion of the tiny particles.
Nanotechnology promises new materials with enhanced properties that perform a variety of roles, including cancer treatment in drugs, stain resistance in clothes and preservatives in food. While there are clear benefits, concerns remain about their safe use.
Dr Gary Hutchison, acting director of Edinburgh Napier’s Centre for Nano Safety, said: ‘Given the widespread use of nanomaterials in variety of everyday products, it is essential for us fully to understand them and their potential impact. We are working with other European specialists on the InLiveTox project to develop a viable, effective alternative to using animals in such testing.
‘A recent change in European chemical safety legislation means that there is a requirement for information on the toxicity of all materials used in significant quantities by 2018. This means there is pressure to investigate thoroughly how substances affect humans in the long term. Animal testing has long been a way of establishing this but it is highly controversial. It is estimated that 3.9 million animals may be needed to adhere to the regulations. Ideally we want to play a part in reducing that number.’
The Centre for Nano Safety is part of Edinburgh Napier University’s Institute for Science & Health Innovation. Its toxicologists work with industry towards the safe use and understanding of the impact of nanomaterials in a variety of everyday products.
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Read morePoolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Trending Articles
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development
Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend
Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Research & Development
Global myalgic encephalomyelitis study identifies 250+ core genes and shared biology with long COVID
PrecisionLife’s large-scale genomic analysis reveals major biological drivers of ME and its overlap with long COVID, identifying dozens of drug repurposing opportunities and paving the way for more targeted clinical trials
Research & Development
Servier and University College London partner to advance research in rare genetic epileptic disorders
Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
Research & Development
EU chemicals reforms rarely reflected in pharmaceutical policy, new study finds
A new analysis shows major EU Green Deal-driven chemicals legislation changes are seldom integrated into pharmaceutical policy, highlighting the need for closer alignment between health and environmental regulation